SEC Form 4 · accession 0001209191-17-045270
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — President & CEO · Director
Period of report
Jul 12, 2017
Accepted (ET)
Jul 14, 2017 · 8:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jul 12, 2017 | S | 2,850 | $20.0025 | D | 198,964 | I | By Matthew R. Patterson Revocable Trust |
| Common StockF4,F3 | Jul 13, 2017 | S | 12,150 | $20.0043 | D | 186,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2Represents the average weighted sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.03. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- F3The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F4Represents the average weighted sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.06.